AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer

Loading...
Loading...
  • AstraZeneca Plc AZN said that China’s health regulator had expanded the use of Tagrisso in patients with a type of lung cancer when diagnosed at an early stage.
  • China’s National Medical Products Administration (NMPA) approved Tagrisso as adjuvant therapy for early-stage lung cancer patients who have a mutation of the EGFR gene.
  • The drug is now approved to treat early-stage lung cancer in more than a dozen countries, including, most recently, in the United States.
  • The Chinese approval was based on positive results from a late-stage trial that showed Tagrisso cut the risk of disease recurrence or death by 83%.
  • Price Action: AZN shares are up 1.46% at $49.91 in premarket trading on the last check Wednesday.
Posted In: BiotechNewsHealth CareFDAGeneralBriefslung cancerNational Medical Products Administration
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...